Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -30.67% is in line with its 5-year average of -29.40%, around the middle of its 5-year range (-44.86%–-16.42%).
As of the fiscal period ended Tuesday, June 30, 2026. 54.04% below its 12-month average of -19.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -30.67%.
RETURN ON EQUITY (ROE)
-30.67%
RETURN ON EQUITY (ROE) AVG TTM
-19.91%
RETURN ON EQUITY (ROE) AVG 3Y
-31.47%
RETURN ON EQUITY (ROE) AVG 5Y
-29.40%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-54.04%
CURRENT VS 3Y AVG
+2.54%
CURRENT VS 5Y AVG
-4.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+26.99%
vs the sector median at left
Twist Bioscience Corporation
Market Cap
$10.40B
Return on Equity (ROE)
-30.67%
TTM Avg
-19.91%
3Y Avg
-31.47%
5Y Avg
-29.40%
Market Cap
$10.31B
Return on Equity (ROE)
11.23%
TTM Avg
7.12%
3Y Avg
6.90%
5Y Avg
7.16%
Market Cap
$10.24B
Return on Equity (ROE)
-9.10%
TTM Avg
-15.59%
3Y Avg
-21.55%
5Y Avg
-27.79%
Market Cap
$10.19B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
Market Cap
$10.15B
Return on Equity (ROE)
N/A
TTM Avg
77.45%
3Y Avg
86.84%
5Y Avg
112.62%
Market Cap
$10.13B
Return on Equity (ROE)
9.77%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$10.72B
Return on Equity (ROE)
20.31%
TTM Avg
18.80%
3Y Avg
15.17%
5Y Avg
15.31%
Market Cap
$10.03B
Return on Equity (ROE)
15.51%
TTM Avg
15.81%
3Y Avg
15.92%
5Y Avg
17.27%
Market Cap
$10.87B
Return on Equity (ROE)
1.15%
TTM Avg
6.63%
3Y Avg
4.94%
5Y Avg
6.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Twist Bioscience Corporation (TWST) | $10.40B | -30.67% | -19.91% | -31.47% | -29.40% |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 11.23% | 7.12% | 6.90% | 7.16% |
| 10x Genomics, Inc. (TXG)vs › | $10.24B | -9.10% | -15.59% | -21.55% | -27.79% |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | -0.17% | 18.91% | 22.60% | 24.60% |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | 77.45% | 86.84% | 112.62% |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 9.77% | 10.54% | 10.84% | 19.93% |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 20.31% | 18.80% | 15.17% | 15.31% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 15.51% | 15.81% | 15.92% | 17.27% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | 1.15% | 6.63% | 4.94% | 6.51% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 3.10% | -8.94% | -15.72% | 1.14% |
ROE
-30.7%
ROA
-20.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -30.67% |
| 2026-03-31 | -17.86% |
| 2025-12-31 | -16.79% |
| 2025-09-30 | -16.42% |
| 2025-06-30 | -17.81% |
| 2025-03-31 | -43.43% |
| 2024-12-31 | -43.28% |
| 2024-09-30 | -44.16% |
| 2024-06-30 | -44.86% |
| 2024-03-31 | -34.30% |
| 2023-12-31 | -34.88% |
| 2023-09-30 | -32.82% |
| 2023-06-30 | -31.86% |
| 2023-03-31 | -30.20% |
| 2022-12-31 | -28.69% |
| 2022-09-30 | -27.60% |
| 2022-06-30 | -25.34% |
| 2022-03-31 | -21.72% |
| 2021-12-31 | -26.31% |
| 2021-09-30 | -26.19% |
| 2021-06-30 | -22.14% |
| 2021-03-31 | -20.08% |
| 2020-12-31 | -18.37% |
| 2020-09-30 | -41.61% |
| 2020-06-30 | -42.07% |
| 2020-03-31 | -55.45% |
| 2019-12-31 | -136.46% |
| 2019-09-30 | -70.80% |
| 2019-06-30 | -54.71% |
| 2019-03-31 | -74.47% |
| 2018-12-31 | -55.51% |
| 2018-06-30 | -70.96% |
